12596363

Source:http://linkedlifedata.com/resource/pubmed/id/12596363

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0039421, umls-concept:C0220825, umls-concept:C0338246
pubmed:issue	6
pubmed:dateCreated	2003-2-24
pubmed:abstractText	Therion Biologics, in collaboration with Aventis Pasteur, is developing ALVAC-CEA/B7.1, a recombinant, pox virus-based vaccine that targets carcinoembryonic antigen (CEA) found on the surface of lung and colorectal tumor cells, for the potential treatment of lung and colorectal cancer. The vaccine is in phase II clinical trials for these indications.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100891485
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/ALVAC-CEA vaccine, http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	1464-8431
pubmed:author	pubmed-author:ErtlHildegund C JHC
pubmed:issnType	Print
pubmed:volume	4
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	601-5
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:12596363-Animals, pubmed-meshheading:12596363-Cancer Vaccines, pubmed-meshheading:12596363-Clinical Trials, Phase I as Topic, pubmed-meshheading:12596363-Colorectal Neoplasms, pubmed-meshheading:12596363-Drug Evaluation, pubmed-meshheading:12596363-Humans, pubmed-meshheading:12596363-Lung Neoplasms, pubmed-meshheading:12596363-Technology, Pharmaceutical, pubmed-meshheading:12596363-Vaccines, Synthetic
pubmed:year	2002
pubmed:articleTitle	Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
pubmed:affiliation	Wistar Institute, 3600 Spruce Street, Philadelphia, PA 19104, USA. ertl@wistar.upenn.edu
pubmed:publicationType	Journal Article, Review